China's Dermatitis-Eczema Drug Market Surges +48.5% as Biologics Reshape Treatment Landscape

Executive Summary

Dermatitis and eczema prescription drugs have emerged as the dominant growth engine in China's online dermatological market, capturing 30.36% market share with +48.5% year-on-year growth in January-July 2024^[1]. JD.com (京东) has nearly doubled its monthly run rate in this segment, from CN¥ 10-17 million per month in early 2023 to CN¥ 22-35 million in 2024, driven by the growing share of expensive biologic drugs that now account for 21.1% of the platform's dermatitis-eczema sales. Meanwhile, market concentration is declining as the top brand's share fell from 18.4% to 10.6%, signaling intensifying competition that will reshape the competitive landscape.

Dermatitis-Eczema Leads All RX Sub-segments

Dermatitis-eczema drugs grew from CN¥ 226 million to CN¥ 336 million in January-July 2024, a CN¥ 110 million absolute increase that represents the single largest growth contributor in the prescription dermatological market^[1]. This +48.5% surge reflects several converging factors: increasing disease prevalence driven by environmental and lifestyle changes, improved access to effective treatments through e-prescription channels, and growing consumer willingness to purchase prescription medications online.

Among the top 10 RX sub-segments, fungal infection treatments (+28.4% YoY) and wart/herpes medications (approximately +57% YoY) also showed strong growth, while the scar treatment segment maintained stable sales at CN¥ 150-153 million.

Dermatitis-eczema leads RX segments at CN¥ 3.36 billion (+48.5% YoY), followed by scar treatment and fungal infection drugs

JD.com Doubles Its Monthly Sales

JD.com's dermatitis-eczema monthly sales reached CN¥ 34.7 million in April 2024 -- nearly triple its January 2023 level of CN¥ 10.7 million^[1]. This acceleration reflects JD.com's strategic investment in pharmaceutical logistics, online consultation services, and professional pharmacy positioning.

In contrast, Taobao/Tmall (淘系) showed more modest growth from the CN¥ 15-18 million range to CN¥ 19-24 million per month, maintaining its absolute lead but losing relative momentum. Combined monthly sales volume exceeded 1 million units in mid-2024, up from 581,000 units in January 2023, confirming that volume growth is a primary driver alongside price appreciation.

JD.com dermatitis-eczema RX sales nearly doubled from CN¥ 10.7 million (Jan 2023) to CN¥ 31.7 million (Jul 2024)

Biologics Drive Premium Pricing on JD.com

The pricing divergence between platforms reveals the transformative impact of biologic drugs on the dermatitis-eczema market^[1]. On JD.com, the 200+ CN¥ price segment expanded from 5.3% of sales in 2022 to 21.1% in 2024, driven by high-cost medications such as upadacitinib (乌帕替尼) and abrocitinib (阿布昔替尼) commanding over CN¥ 1,000 per treatment course.

Meanwhile, Taobao/Tmall has shifted toward affordability: the under-50 CN¥ segment grew from 28.1% to 49.0%, dominated by fusidic acid, halometasone, and desonide generics. This creates two distinct strategic opportunities: JD.com for premium and biologic positioning, Taobao/Tmall for volume-driven mass market access.

Brand Concentration Declining

Market concentration is falling consistently: the top brand's share dropped from 18.4% in 2022 to 10.6% in 2024, while the combined top 5 share declined from approximately 48% to 35%^[1]. This deconcentration reflects the maturation of the market as multiple brands achieve therapeutic equivalence and compete on pricing, brand trust, and platform positioning.

Notably, consumer purchase decisions are becoming more efficacy-driven: brand influence dropped from 3.8% to 1.3% of purchase decision factors, while disease scenario/use case (38.1%) and product category awareness (18.4%) dominate.